Page last updated: 2024-10-26

dipyridamole and Rupture

dipyridamole has been researched along with Rupture in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Rupture: Forcible or traumatic tear or break of an organ or other soft part of the body.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benzimra, JD1
Johnston, RL1
Jaycock, P1
Galloway, PH1
Lambert, G1
Chung, AK1
Eke, T1
Sparrow, JM1

Other Studies

1 other study available for dipyridamole and Rupture

ArticleYear
The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications.
    Eye (London, England), 2009, Volume: 23, Issue:1

    Topics: Aged; Anesthetics, Local; Anticoagulants; Aspirin; Blood Loss, Surgical; Cataract Extraction; Choroi

2009